ENO2 and Lymphatic Metastasis: Chemotherapy provided a significant survival benefit in stage III/IV patients, older individuals, males, patients with lymphatic metastasis, and those with normal CEA or NSE levels, supporting its selective efficacy in high-risk or advanced-stage patients (29).